Daniel Calarese
Executive Director, Drug Discovery & Innovation Sutro Biopharma
Seminars
Wednesday 14th October 2026
Breaking Down Preclinical Characterization of STRO-227 Dual Payload ADC to Evaluate Efficacy & Safety in ADC Resistance Models
2:30 pm
- Addressing rationale for dual payload ADC development to combat acquired resistance to single payload ADCs
- Laying out the preclinical profile of STRO-227, highlighting efficacy in models of ADC resistance and NHP safety data
- Looking ahead to STRO-227 IND filing and clinical strategy to benefit patients
